The loss of MyD88 signaling in B cells resulted in increased CD8+ T cell effector responses in the spleen but not in the tumor nor the tumor-draining lymph node upon tumor challenge, suggesting insufficient T cell priming (Figures 3C–E). The gene discussed is MYD88; the disease is neoplasm.